No House member has disclosed a BLCO trade since 2025.
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.2 | 9.6 | -13.1 | 0.0 | -1.6 | 5.8 | 2.1 | 3.4 | -2.7 | -5.5 | −5.9% | ||
| 2025 | -3.9 | -7.8 | -9.4 | -20.3 | -0.8 | 13.4 | 4.8 | 7.3 | 3.0 | -0.9 | 8.4 | 5.5 | −5.4% |
| 2024 | -17.9 | 17.8 | 4.8 | -16.0 | 5.5 | -5.3 | 18.6 | -4.6 | 17.4 | 5.1 | -2.3 | -8.9 | +5.9% |
| 2023 | 11.2 | 1.2 | -0.2 | 0.3 | 2.3 | 12.4 | -1.0 | -9.8 | -5.5 | -4.8 | -4.5 | 10.7 | +10.0% |
| 2022 | -10.4 | -5.6 | 3.4 | 3.1 | -7.0 | 6.1 | 2.5 | −8.8% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 11, 2026 | Paul Laurence E. M.D.Director | Stock Award(Grant) at price 0.00 per share. | 11.8K | — |
| Aug 11, 2026 | Trebbi Barbara J.Director | Stock Award(Grant) at price 0.00 per share. | 11.8K | — |
| Aug 11, 2026 | Chersi Robert J.Director | Stock Award(Grant) at price 0.00 per share. | 11.8K | — |
| Aug 9, 2026 | Munsch Frederick JohnOfficer | Sale at price 16.78 per share. | 52.9K | $887.66K |
| Aug 6, 2026 | Von Eschenbach Andrew CharlesDirector | Sale at price 16.50 - 16.58 per share. | 18.6K | $306.71K |
| Aug 4, 2026 | Saunders Brent L.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 281.9K | — |
| Aug 4, 2026 | Eldessouky Osama AChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 50.3K | — |
| Aug 4, 2026 | Bailey Ambrose Robert Douglas J.D.Officer | Stock Award(Grant) at price 0.00 per share. | 33.6K | — |
| Aug 4, 2026 | Munsch Frederick JohnOfficer | Stock Award(Grant) at price 0.00 per share. | 9.1K | — |
| Aug 4, 2026 | Hashad YehiaOfficer | Stock Award(Grant) at price 0.00 per share. | 21K | — |
| Aug 4, 2026 | Stewart Andrew JudeOfficer | Stock Award(Grant) at price 0.00 per share. | 16.8K | — |
| Aug 4, 2026 | Bonnefoy LucOfficer | Stock Award(Grant) at price 0.00 per share. | 16.8K | — |
| May 25, 2026 | Collis Steven HowardDirector | Stock Award(Grant) at price 15.78 per share. | 15.8K | $249.99K |
| May 25, 2026 | Von Eschenbach Andrew CharlesDirector | Stock Award(Grant) at price 15.78 per share. | 15.8K | $249.99K |
| May 25, 2026 | Ling KarenDirector | Stock Award(Grant) at price 15.78 per share. | 15.8K | $249.99K |
| May 25, 2026 | Ross Thomas W SrDirector | Stock Award(Grant) at price 15.78 per share. | 15.8K | $249.99K |
| May 25, 2026 | Paulson John A.Director | Stock Award(Grant) at price 15.78 per share. | 15.8K | $249.99K |
| May 25, 2026 | Robertson Russel CDirector | Stock Award(Grant) at price 15.78 per share. | 15.8K | $249.99K |
| May 25, 2026 | Kavanagh Sarah BaldwinDirector | Stock Award(Grant) at price 15.78 per share. | 15.8K | $249.99K |
| May 25, 2026 | Bernier Nathalie DDirector | Stock Award(Grant) at price 15.78 per share. | 15.8K | $249.99K |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Buy / hold / sell counts